APRE - Aprea Therapeutics, Inc.

QQQ $ 605.69 $ -5.46 (-0.89 %)

DIA $ 465.20 $ -3.41 (-0.73 %)

SPY $ 667.94 $ -4.13 (-0.61 %)

TLT $ 92.14 $ 0.09 (0.1 %)

GLD $ 377.60 $ 4.47 (1.2 %)

Previous Close

$ 1.51

Open

$ 1.48

Bid

$ 1.44 x 1

Ask

$ 1.63 x 600

Day's Range

$ 1.49 - $ 1.53

52 Week Range

$ 1.37 - $ 5.00

Volume

288,722

Average Volume

Market Cap

8.8M

Beta (5Y Monthly)

$ 1.27

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-12-2025	06-30-2025	10-Q
2	05-14-2025	03-31-2025	10-Q
3	03-25-2025	12-31-2024	10-K
4	11-07-2024	09-30-2024	10-Q
5	08-12-2024	06-30-2024	10-Q
6	05-14-2024	03-31-2024	10-Q
7	03-26-2024	12-31-2023	10-K
8	11-09-2023	09-30-2023	10-Q
9	08-10-2023	06-30-2023	10-Q
10	05-15-2023	03-31-2023	10-Q
11	03-30-2023	12-31-2022	10-K
12	11-09-2022	09-30-2022	10-Q
13	08-12-2022	06-30-2022	10-Q
14	05-16-2022	03-31-2022	10-Q
15	03-15-2022	12-31-2021	10-K
16	11-08-2021	09-30-2021	10-Q
17	08-12-2021	06-30-2021	10-Q
18	05-06-2021	03-31-2021	10-Q
19	03-16-2021	12-31-2020	10-K
20	11-06-2020	09-30-2020	10-Q
21	08-11-2020	06-30-2020	10-Q
22	05-15-2020	03-31-2020	10-Q
23	03-27-2020	12-31-2019	10-K
24	11-14-2019	09-30-2019	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Aprea Therapeutics Determines RP2D Of 1,10...
10/15/2025 12:04:25

ATRN-119 (ATR Inhibitor): RP2D of 1,100 mg once daily identified in ongoing ABOYA-119 dose-escalation studyFurther ATRN-119 mon...

Aprea Therapeutics Announces Two Abstracts...
10/14/2025 12:03:39

Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company ...

12 Health Care Stocks Moving In Wednesday'...
09/17/2025 12:12:13

Aprea Therapeutics Q2 EPS $(0.53) Beats $(...
08/12/2025 12:11:26

Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(...

12 Health Care Stocks Moving In Wednesday'...
07/23/2025 21:05:58

Aprea Therapeutics Presents APR-1051 Precl...
06/25/2025 13:05:43

Preclinical data demonstrate potent single-agent and combination effects in head and neck squamous cell carcinoma (HNSCC) model...

Aprea Therapeutics Q1 EPS $(0.66) Up From ...
05/14/2025 12:14:08

Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.66) per share. This is a 1.49 percent increase over losses of...

Aprea Therapeutics Reports Dosing of Patie...
03/31/2025 12:35:38

12-health-care-stocks-moving-in-mondays-pre-market-session

12 Health Care Stocks Moving In Monday's P...
03/31/2025 12:05:38

Aprea Therapeutics Q4 EPS ($0.49) Up From ...
03/25/2025 12:41:59

Aprea Therapeutics Enters Medical Transfer...
03/11/2025 12:36:23

HC Wainwright & Co. Reiterates Buy on Apre...
01/15/2025 16:03:26

HC Wainwright & Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 pr...

HC Wainwright & Co. Reiterates Buy on Apre...
12/17/2024 12:27:26

HC Wainwright & Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 pr...

Aprea Therapeutics Announces Twice Daily D...
12/11/2024 13:31:53

Twice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea's e...

HC Wainwright & Co. Reiterates Buy on Apre...
11/18/2024 12:40:52

HC Wainwright & Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 pr...

Aprea Therapeutics Q3 EPS $(0.64) Beats $(...
11/07/2024 13:08:29

Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(...

HC Wainwright & Co. Reiterates Buy on Apre...
10/24/2024 09:39:26

HC Wainwright & Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 pr...

Aprea Therapeutics Presents Preliminary Fi...
10/23/2024 12:35:49

Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical n...

12-health-care-stocks-moving-in-tuesdays-intraday-session

12 Health Care Stocks Moving In Tuesday's ...
10/15/2024 16:32:12

Wedbush Reiterates Outperform on Aprea The...
08/13/2024 14:34:10

Wedbush analyst Robert Driscoll reiterates Aprea Therapeutics (NASDAQ:APRE) with a Outperform and maintains $11 price target.